logo
World shares are mixed after U.S. inflation update suggests tariffs are causing prices to rise

World shares are mixed after U.S. inflation update suggests tariffs are causing prices to rise

CTV Newsa day ago
A currency trader works near a screen showing the Korea Composite Stock Price Index (KOSPI), top left, and the foreign exchange rate between U.S. dollar and South Korean won, top center, at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Tuesday, July 15, 2025. (AP Photo/Ahn Young-joon)
BANGKOK — Shares were mixed Wednesday in Europe and Asia after an update on U.S. inflation pulled most Wall Street stocks lower, though gains for Nvidia pushed the Nasdaq to another record.
The report showed inflation in the United States accelerated to 2.7% last month from 2.4% in May. Economists said higher prices for clothes, toys and other goods that usually are imported suggest stiffer tariffs that President Donald Trump has imposed on other countries are fueling inflation.
Germany's DAX edged 0.1% higher to 24,074.54, while the CAC 40 in Paris shed 0.1% to 7,755.90. Britain's FTSE 100 was up 0.1% at 8,950.11.
The future for the S&P 500 fell less than 0.1% while that for the Dow industrials was little changed.
In Asian trading, tokyo's Nikkei 225 edged less than 0.1% lower, to 39,663.40. Investors are focusing on the potential impact of an election for the Upper House of Parliament on Sunday that is expected to lead to tax cuts and higher spending as lawmakers try to restore the waning popularity of the ruling Liberal Democrats.
Worries over a deterioration in Japan's fiscal health have pushed yields of long-term Japanese government bonds to their highest levels in years.
'What's at stake isn't simply which party hands out the biggest bundle of goodies. It's whether the walls holding up Japan's house of debt can withstand another round of fiscal fireworks…' Stephen Innes of SPI Asset Management said in a commentary.
Elsewhere in Asia, Hong Kong's Hang Seng shed 0.3% to 24,517.76, while the Shanghai Composite index slipped less than 0.1% to 3,503.78.
South Korea's Kospi lost 0.9% to 3,186.38 and in Australia, the S&P/ASX 200 declined 0.8% to 8,561.80.
Taiwan's Taiex jumped 0.9% and India's Sensex added 0.2%. Thailand's SET dropped 0.3%.
In Jakarta, shares rose 0.7% after President Donald Trump said on Truth Social that he plans to charge imports from Indonesia a tariff of 19%, while American goods sent to the Southeast Asian country will face no tariffs. Trump also said Indonesia committed to buying U.S. energy, agricultural products and aircraft.
On Tuesday, the S&P 500 fell 0.4%, staying near its all-time high set last week. The Dow Jones Industrial Average dropped 1%, while the Nasdaq composite rose 0.2% to a record 20,677.80 thanks to Nvidia, the market's most influential stock.
Nvidia said the U.S. government has assured it that licenses will be granted for its H20 chip, used for artificial intelligence, again and that deliveries will hopefully begin soon. Its 4% gain was by far the strongest force pushing upward on the S&P 500.
Wall Street loves lower interest rates because they goose prices higher for stocks and other investments, and Trump himself has been clamoring for the Federal Reserve to cut rates more quickly. But the Fed has been keeping interest rates on hold this year since lower rates can give inflation more fuel while they boost the economy. Fed Chair Jerome Powell has insisted he wants to see more data about how tariffs affect the economy and inflation.
In other dealings early Wednesday, U.S. benchmark crude oil shed 21 cents to $66.31 per barrel. Brent crude, the international standard, slipped 31 cents at $68.40 per barrel.
The dollar fell to 148.79 Japanese yen from 148.87 yen. The euro was at $1.1630, up from $1.1602.
Elaine Kurtenbach, The Associated Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Rue Canada': Vermont town hopes to lure Canadians by temporarily renaming major shopping street
‘Rue Canada': Vermont town hopes to lure Canadians by temporarily renaming major shopping street

Montreal Gazette

time21 minutes ago

  • Montreal Gazette

‘Rue Canada': Vermont town hopes to lure Canadians by temporarily renaming major shopping street

By Burlington, Vt. is temporarily naming a major shopping street after Canada in hopes of attracting Canadian tourists who have eschewed U.S. travel since President Donald Trump took office. The town rechristened Church St., a popular shopping street for visitors, as Canada St. in a ceremony Wednesday. Signs reading 'Rue Canada St.' are set to remain in place until Sept. 1. The move was a 'symbolic gesture' designed to show that 'Trump's policies are not in line with our values,' said Burlington city councillor Becca Brown McKnight. Those policies, which include aggressive tariffs alongside threats to annex Canada as a '51st state,' have caused a sharp deterioration in cross-border relations. Canadians, including Quebecers, are travelling to the U.S. in smaller numbers than before. In June, 164,000 Quebecers travelled to the U.S., a 43-per-cent drop from the 286,000 who made the trip in June 2024. Canadian tourism offers a significant boost to the Burlington and Vermont economies, McKnight said. 'More Canadians come to Vermont each year than people who live here.' Around 581,000 Canadians visited Vermont between January and May 2025, a 23-per-cent drop from 2024, according to the state's Agency of Commerce and Community Development. Fewer tourists have made for less spending, with the agency reporting a 41-per-cent drop in Canadian credit card spending in the first five months of 2025 compared with the year-earlier period. Reduced tourism is bad news for Burlington, McKnight said, where around 15 per cent of the town's downtown spending typically originates from Canadians. Locals have noticed the decline and 'are hearing French spoken less often,' she said. McKnight said she has already heard positive feedback from Canadians, who she said have told her they plan to visit Burlington this year. But she also acknowledged that some Canadians don't feel comfortable making the trip to the U.S. 'I completely understand that.' Vermonters in Burlington enjoy travel to Quebec, McKnight said, adding that she spent her honeymoon in Montreal.

Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat

Globe and Mail

time21 minutes ago

  • Globe and Mail

Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat

Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter's level. GAAP EPS was $1.01 compared with 74 cents in the second quarter of 2024. Following the earnings announcement, ABT stock fell 5% at pre-market trading today. The share price drop might be due to its reserved third-quarter guidance, which came in slightly below the Zacks Consensus Estimate. ABT's Q2 Revenues Worldwide sales of $11.14 billion were up 7.4% year over year on a reported basis. The top line surpassed the Zacks Consensus Estimate by 0.6%. Organically, sales improved 6.9% year over year. Organic sales, ex-COVID rose 7.5% year over year. ABT's Q2 Results in Detail Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics. Established Pharmaceuticals ' product sales increased 6.9% on a reported basis (7.7% on an organic basis) to $1.38 billion. Organic sales in key emerging markets improved 8.7% year over year. This was led by double-digit growth in several countries, including Asia, Latin America and the Middle East. In the second quarter, the Medical Devices segment's sales rose 13.4% year over year on a reported basis (12.2% organically) to $5.37 billion. Sales growth was led by Diabetes Care, Structural Heart and Heart Failure and Electrophysiology. Several products, including FreeStyle Libre, Navitor, TriClip, and AVEIR, contributed to the strong performance. The Diabetes Care division reported organic sales growth of 19.6% year over year, led by sales of continuous glucose monitors, which accounted for $1.90 billion of total sales. Structural Heart sales rose 11.7%, and Heart Failure sales improved 14% year over year organically. The Vascular division recorded organic sales growth of 3.5%. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 10.3%, 9.8% and 4.3%, respectively, in the quarter under review. For the second quarter, Nutrition sales rose 2.9% year over year on a reported basis (up 3.4% organically) to $2.21 billion. Pediatric Nutrition sales were up 0.2%, and Adult Nutrition sales improved 6.6% organically. According to the company, Adult Nutrition sales benefited from the strong global growth of Ensure and Glucerna, Abbott's market-leading brands. For the second quarter, Diagnostics sales declined 1% year over year on a reported basis (down 1.4% organically) to $2.17 billion. Organic sales, ex-COVID, rose 0.8%. Core Laboratory Diagnostics sales were up 1.6% organically. Molecular Diagnostics' sales declined 3.4% on an organic basis. Rapid Diagnostics sales were down 6.8%. Point of Care Diagnostics sales decreased 5.2%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Margin Details of ABT In the second quarter, the gross profit rose 8.9% year over year to $6.29 billion despite a 5.4% increase in the cost of products sold (excluding amortization expense). The gross margin expanded 79 basis points (bps) to 56.4%. Selling, general and administration expenses rose 5.3% year over year to $3.09 billion. Research and development expenses rose 3.9% year over year to $725 million. The company reported an adjusted operating profit of $2.47 billion, up 15.5% year over year. Also, the adjusted operating margin expanded 156 bps to 22.2%. ABT's 2025 Financial Guidance Abbott expects full-year adjusted diluted EPS to be in the range of $5.10-$5.20 (earlier $5.05-$5.25). The Zacks Consensus Estimate for the metric is pegged at $5.16. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. The Zacks Consensus Estimate for sales is currently pegged at $44.70 billion, suggesting a 6.6% improvement from the 2024 level. For the third quarter of 2025, adjusted diluted EPS is expected to be between $1.28 and $1.32. The Zacks Consensus Estimate for the metric is pegged at $1.34. Our Take Abbott exited the second quarter of 2025 with better-than-expected results. Both its earnings and revenues beat their respective estimates. Additionally, the figures improved on a year-over-year basis. All business segments experienced growth during the reported quarter, except Diagnostics. Meanwhile, Abbott's Diagnostics sales growth continued to be adversely impacted by year-over-year declines in COVID-19 testing-related sales, along with volume-based procurement programs in China. During the reported quarter, Abbott announced favorable data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. Additionally, the company received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system — a first-of-its-kind device to help treat people with mitral valve disease. Meanwhile, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia, expected to be completed by 2028. In addition, the expansion of both margins is encouraging. ABT's Zacks Rank and Other Key Picks Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Boston Scientific BSX. Veeva Systems, currently sporting a Zacks Rank #2, reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Boston Scientific, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report

2025: Wall Street's Steep Ascent Up the Wall of Worry
2025: Wall Street's Steep Ascent Up the Wall of Worry

Globe and Mail

time21 minutes ago

  • Globe and Mail

2025: Wall Street's Steep Ascent Up the Wall of Worry

Wall Street Climbs the Proverbial Wall of Worry in 2025 No two years on Wall Street are the same. However, 2025 is an extreme example of how one year can differ from the next. 2024 was marked by a dovish Federal Reserve board and a slow grind higher in the major market indices. 2025 started with a returning administration in Washington DC (albeit four years later), the 'DeepSeek' scare, and the 'Liberation Day' fallout. First, a Chinese company released the 'DeepSeek' chatbot, which had similar performance to OpenAI and Microsoft's ( MSFT ) wildly popular 'ChatGPT' large language model, and was allegedly 'trained' at a fraction of the cost, suggesting that the company had found the holy grail of AI. In the following weeks, AI leaders such as Nvidia ( NVDA ), Alphabet ( GOOGL ), Arm Holdings ( ARM ), and Advanced Micro Devices ( AMD ) would suffer swift losses as China threatened to take the lead in the high-stakes race for artificial intelligence supremacy. Then, on April 2 nd, President Donald Trump announced a sweeping package of tariffs on hundreds of countries, accelerating the losses and sending stocks into bear market territory. On April 9 th, President Trump announced a 90-day pause on 'reciprocal tariffs and stocks soared. Since then, stocks reacted positively to a preliminary and unexpected trade deal between the US and its largest trading partner, China. Finally, despite rampant investor fears, stocks exhibited resilience and shook off a targeted US attack on Iranian nuclear plants. 3 Trading Takeaways from 2025 Savvy investors understand that there are always lessons to be learned. Three of my key takeaways include: 1. Time Heals on Wall Street: Whether it was DeepSeek or the tariff fallout, the US market tends to shake off bad news as time passes. 2. Headlines can be a Distraction: Nearly every economist on Wall Street predicted that the Trump tariff policy would cause rampant inflation. In reality, the inflation rate is hovering near its lowest level in multiple years. 3. Price Action is Truth: The 21-day moving average is a fantastic intermediate-term guide for investors. In the first part of the year, it warned investors to stay out of the once the market regained the 21-day moving average, it never looked back. Bottom Line It's been a turbulent year, but 2025 has once again proven Wall Street's ability to climb the proverbial 'wall of worry.' From the initial DeepSeek shock and the tariff scares, the market has demonstrated remarkable resilience. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report ARM Holdings PLC Sponsored ADR (ARM): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store